The Column Group
The Column Group is a leading venture capital firm dedicated to creating the next generation of biotechnology companies. We will deploy our first fund of approximately $260M to build 8-10 disease-focused drug discovery companies, each with the potential to become a leader in their respective field(s). These companies will be strongly supported by the unique and complementary skill-sets of our team, which includes prominent authorities in the scientific, operational and financial arenas. Typically, we will commit $20M to $30M per company, fostering their growth from seed and early stage to later stages of development. The Column Group seeks to partner with exceptional scientific founders, entrepreneurs, executives and investment organizations that share our vision for building the next generation of drug discovery and development companies.
5AM Ventures is a seed and early-stage venture capital firm focused on building next-generation life science companies. Founded in 2002, 5AM Ventures has over $200 million under management and is actively investing its second fund. As successful former company leaders and established venture capitalists, the 5AM team takes a hands-on approach to company building. In addition to leading investments and contributing as board members of its portfolio companies, 5AM is directly involved in company strategy, management recruiting, business development and fundraising and often takes on short-term operating roles. The firm has offices in Menlo Park, CA and Waltham, MA.
OrbiMed is a leading investment firm dedicated exclusively to the healthcare sector. With $7 billion in assets under management, OrbiMed invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies. OrbiMed’s team manages a series of private equity funds, public equity funds, royalty and debt funds, and other investment vehicles.
Third Rock Ventures
Third Rock Ventures was founded in 2007 with the mission to launch transforming companies. We set out to build a different firm – a firm that was squarely focused on launching exceptional life science companies with passionate entrepreneurs, working in areas of disruptive science to make a difference in the lives of patients. In just three short years, and during a period of time when early stage investing has been in flux, we have successfully raised more than $800 million to accomplish this mission. We truly believe that nothing is impossible.